Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Vertex Pharmaceuticals Inc., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in thousands

	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021
Accounts payable	461,700)	420,300)	442,300)	445,000)	413,000)	395,800)	327,900)	351,400)	364,900)	375,900)	363,000)	323,200)	303,900)	126,900)	198,000)	173,600)	195,000)	127,863)	127,534)	127,839)
Accrued expenses	2,971,200)	3,613,500)	3,270,700)	2,951,800)	2,788,600)	3,219,700)	2,940,000)	2,795,900)	2,655,300)	2,907,300)	2,598,100)	2,326,000)	2,126,700)	2,264,400)	2,119,500)	1,720,500)	1,678,600)	1,584,992)	1,482,556)	1,532,037)
Other current liabilities	428,300)	441,500)	425,400)	386,400)	363,000)	357,600)	279,300)	648,600)	527,200)	316,200)	391,000)	377,000)	311,500)	218,000)	238,700)	286,100)	268,400)	201,409)	226,358)	284,174)
Current liabilities	3,861,200)	4,475,300)	4,138,400)	3,783,200)	3,564,600)	3,973,100)	3,547,200)	3,795,900)	3,547,400)	3,599,400)	3,352,100)	3,026,200)	2,742,100)	2,609,300)	2,556,200)	2,180,200)	2,142,000)	1,914,264)	1,836,448)	1,944,050)
Long-term operating lease liabilities	1,846,500)	1,834,800)	1,527,400)	1,537,700)	1,544,400)	1,588,900)	586,800)	359,800)	348,600)	354,400)	363,500)	371,600)	379,500)	382,300)	365,000)	377,000)	377,400)	363,545)	368,924)	368,467)
Other long-term liabilities	1,269,500)	1,233,400)	1,195,500)	1,063,300)	1,014,600)	1,047,300)	1,223,400)	1,215,100)	1,253,800)	1,259,600)	1,163,400)	1,144,100)	1,116,600)	685,200)	727,500)	791,900)	813,100)	810,228)	819,918)	822,288)
Long-term liabilities	3,116,000)	3,068,200)	2,722,900)	2,601,000)	2,559,000)	2,636,200)	1,810,200)	1,574,900)	1,602,400)	1,614,000)	1,526,900)	1,515,700)	1,496,100)	1,067,500)	1,092,500)	1,168,900)	1,190,500)	1,173,773)	1,188,842)	1,190,755)
Total liabilities	6,977,200)	7,543,500)	6,861,300)	6,384,200)	6,123,600)	6,609,300)	5,357,400)	5,370,800)	5,149,800)	5,213,400)	4,879,000)	4,541,900)	4,238,200)	3,676,800)	3,648,700)	3,349,100)	3,332,500)	3,088,037)	3,025,290)	3,134,805)
Preferred stock, $0.01 par value; none issued	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Common stock, $0.01 par value	2,500)	2,500)	2,600)	2,600)	2,600)	2,600)	2,600)	2,600)	2,600)	2,600)	2,600)	2,600)	2,600)	2,600)	2,600)	2,600)	2,500)	2,562)	2,591)	2,588)
Additional paid-in capital	5,119,200)	5,011,900)	5,987,900)	6,172,500)	6,672,400)	6,905,700)	7,101,200)	7,284,700)	7,449,700)	7,339,600)	7,369,100)	7,220,200)	7,386,500)	7,225,500)	7,100,000)	6,930,200)	6,880,800)	7,085,950)	7,640,233)	7,499,161)
Accumulated other comprehensive income (loss)	(15,900)	(64,500)	(101,100)	68,100)	127,800)	28,800)	22,500)	17,300)	(14,300)	(3,000)	(39,800)	(13,100)	800)	97,600)	57,500)	11,300)	15,900)	11,537)	(25,159)	(33,302)
Retained earnings	13,560,000)	12,368,900)	11,286,000)	10,253,100)	9,606,800)	8,693,800)	7,648,400)	11,242,000)	10,142,400)	9,173,600)	8,138,300)	7,222,600)	6,522,800)	5,703,900)	4,773,400)	3,962,900)	3,200,800)	2,430,659)	1,578,731)	1,511,807)
Shareholders’ equity	18,665,800)	17,318,800)	17,175,400)	16,496,300)	16,409,600)	15,630,900)	14,774,700)	18,546,600)	17,580,400)	16,512,800)	15,470,200)	14,432,300)	13,912,700)	13,029,600)	11,933,500)	10,907,000)	10,100,000)	9,530,708)	9,196,396)	8,980,254)
Total liabilities and shareholders’ equity	25,643,000)	24,862,300)	24,036,700)	22,880,500)	22,533,200)	22,240,200)	20,132,100)	23,917,400)	22,730,200)	21,726,200)	20,349,200)	18,974,200)	18,150,900)	16,706,400)	15,582,200)	14,256,100)	13,432,500)	12,618,745)	12,221,686)	12,115,059)

Overall, the liabilities and stockholders’ equity of the company demonstrate a general upward trend throughout the observed period, with some notable fluctuations. Total liabilities increased significantly over the timeframe, while shareholders’ equity also exhibited growth, though with periods of decline. A substantial increase in both categories is evident from 2022 onwards.

Current Liabilities: Current liabilities generally increased from approximately US$1.94 billion in March 2021 to US$3.599 billion in September 2023, before decreasing to US$3.861 billion in December 2025. Accounts payable and accrued expenses are the primary components of current liabilities, with accrued expenses consistently representing the largest portion. Accounts payable show considerable volatility, peaking at US$461.7 million in December 2025, while accrued expenses steadily increased from US$1.532 billion to US$2.971 billion before decreasing to US$3.613 billion. Other current liabilities also contributed to the overall increase, though to a lesser extent.
Long-Term Liabilities: Long-term liabilities also increased over the period, rising from approximately US$1.191 billion in March 2021 to US$3.116 billion in December 2025. The most significant driver of this increase was long-term operating lease liabilities, which experienced a substantial jump from US$368.467 billion in March 2021 to US$1.846 billion in December 2025. Other long-term liabilities also increased, but at a more moderate pace, moving from US$822.288 billion to US$1.269 billion.
Shareholders’ Equity: Shareholders’ equity demonstrated an overall upward trend, increasing from approximately US$8.980 billion in March 2021 to US$18.666 billion in December 2025. Retained earnings were the primary contributor to this growth, increasing from US$1.512 billion to US$13.560 billion. Additional paid-in capital also contributed, though its growth was less pronounced, and experienced a decline from US$7.499 billion to US$5.012 billion. Accumulated other comprehensive income (loss) fluctuated throughout the period, ending at a loss of US$15.9 million in December 2025. Common stock remained relatively stable.
Total Liabilities and Shareholders’ Equity: The combined total of liabilities and shareholders’ equity increased from US$12.115 billion in March 2021 to US$25.643 billion in December 2025. This increase reflects the growth observed in both liabilities and equity. The most substantial increase occurred between 2022 and 2024, indicating a period of significant expansion or investment.

In summary, the company experienced substantial growth in both liabilities and shareholders’ equity over the analyzed period. The increase in liabilities was primarily driven by long-term operating lease obligations and accrued expenses, while the growth in shareholders’ equity was largely attributable to increased retained earnings. These trends suggest a period of expansion and investment, potentially funded through a combination of debt and internally generated funds.

AI Ask an analyst for more

Download chart

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

Balance Sheet: Liabilities and Stockholders’ Equity Quarterly Data

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data